冠心平治疗冠心病120例临床总结及其抗凝机制的研究

Clinical Study on 120 Cases of Coronary Heart Disease Treated by Guanxinping and Its Anticoagulant Mechanism

摘要: 目的:通过观察冠心平治疗冠心病(CHD)心绞痛患者血小板颗粒膜蛋白140 (GMP-140)、D-二聚体水平、血液流变学以及临床症状和心电图等疗效指标的改变，评估冠心平治疗CHD心绞痛的临床疗效。方法：选取120例CHD心绞痛患者,随机分为治疗组和对照组各60例，治疗组采用基础治疗联合口服冠心平片，每次4片，每日3次；对照组采用基础治疗联合口服心可舒片，每次4片，每日3次。两组均连续治疗4周。评价患者临床症状、心电图指标、综合疗效，以及血浆GMP-140、D-二聚体、血流变水平治疗前后的变化。结果：治疗组CHD心绞痛患者在临床症状、心电图指标、中医疗效、综合疗效方面均优于对照组(P < 0.05或P < 0.01)。治疗后治疗组血浆GMP-140、D-二聚体水平与治疗前相比均显著降低，P < 0.01，且显著低于治疗后的对照组，P < 0.01。治疗后治疗组血流变水平与治疗前相比显著下降，P < 0.01，且与治疗后对照组相比下降明显，P < 0.05。结论:冠心平片治疗CHD心绞痛疗效确切，能改善心绞痛患者的临床症状，缩短发作持续时间，减少发作次数，并能降低血浆GMP-140、D-二聚体、血液流变学水平。

Abstract: Objective: To evaluate the clinical effect of Guanxinping on angina pectoris of coronary heart disease (CHD) by observing the changes of platelet granular membrane protein 140 (GMP-140), D-dimer level, hemorheology, clinical symptoms and electrocardiogram. Method: 120 patients with CHD angina pectoris were randomly divided into treatment group and control group, 60 cases in each group. The treatment group was treated with basic treatment combined with oral Guanxinping tablets, 4 tablets each time, 3 times a day; the control group was treated with basic treatment combined with oral Xinkeshu tablets, 4 tablets each time, 3 times a day. The two groups were treated for 4 weeks. The changes of clinical symptoms, electrocardiogram (ECG), comprehensive efficacy, plasma GMP-140, D-dimer and hemorheological levels before and after treatment were evaluated. Result: The treatment group was superior to the control group in clinical symptoms, electrocardiogram index, curative effect of traditional Chinese medicine and comprehensive curative effect (P < 0.05 or P < 0.01). The plasma levels of GMP-140 and D-dimer in the treatment group were significantly lower than those before treatment (P < 0.01), and significantly lower than those in the control group (P < 0.01). After treatment, the level of blood rheology in the treatment group was significantly lower than that before treatment (P < 0.01), and significantly lower than that in the control group (P < 0.05). Conclusion: Guanxinping has a definite curative effect on CHD angina pectoris. It can improve the clinical symptoms of patients with angina pectoris, shorten the duration of attack, reduce the number of attacks, and reduce the plasma levels of GMP-140, D-dimer and hemorheology.